Category: Metabolic health

According to clinical trials, the rate of acute gallbladder disease, such as gallstones, in Mounjaro-treated patients was approximately 0.6%, emphasizing that the drug itself can pose a risk to the gallbladder. However, the good news for those who have had the organ removed is that Mounjaro is generally considered safe without a gallbladder, though with specific considerations for managing digestive side effects.

An estimated 40% of young U.S. adults between 18 and 44 are insulin-resistant [1.6.1]. The question of whether the pill helps with insulin resistance is complex, as effects vary based on the pill's formulation and a woman's underlying health conditions like PCOS [1.4.6].

While Ozempic is not officially FDA-approved for treating insulin resistance alone, clinical evidence indicates it significantly improves insulin sensitivity, often prescribed off-label for this purpose. Understanding how Ozempic works is key to its role in managing metabolic health.

Over 80% of individuals with obesity experience insulin resistance, prompting many to question: **Will semaglutide work if I have insulin resistance?** Clinical trials and real-world studies confirm that semaglutide, through its powerful effects on weight management and blood sugar control, can significantly improve insulin sensitivity.

According to the CDC, over 100 million Americans have diabetes or prediabetes, conditions rooted in insulin resistance. For individuals with insulin resistance, Ozempic, or its active ingredient semaglutide, has emerged as a significant therapeutic option that can help improve insulin sensitivity and manage related metabolic dysfunctions.

The human body reacts to surgery and anesthesia with a complex stress response that triggers significant metabolic changes. This reaction mobilizes the body's energy reserves but can also lead to temporary issues like insulin resistance, addressing the question of whether or not can anesthesia change your metabolism.

According to the CDC, over a third of U.S. adults have prediabetes, a state characterized by high insulin resistance. For many individuals, tackling this condition requires more than just lifestyle changes, leading to the question: **What is the first line drug for insulin resistance?** The answer, widely supported by decades of clinical evidence, is the biguanide medication metformin.

According to meta-analyses, second-generation antipsychotics like clozapine and olanzapine are consistently associated with the highest risk of metabolic syndrome. This poses a serious health concern, increasing the risk of conditions such as diabetes and heart disease for patients undergoing treatment.

Although Abilify is considered a lower-risk atypical antipsychotic for metabolic side effects, the official drug safety information clearly states that increases in fat levels (cholesterol and **triglycerides**) in the blood are a possible side effect. As with any medication, individual responses can vary, and metabolic changes are a documented risk associated with antipsychotic drug use.

According to the CDC, nearly half of US adults were obese in 2020, leading to increased interest in medications like Mounjaro to combat weight-related health issues. A common worry for those considering this treatment is: does Mounjaro mess with your metabolism? The scientific evidence suggests the opposite, indicating that Mounjaro works to correct underlying metabolic dysfunction rather than create new problems.